Main content

Files | Discussion Wiki | Discussion | Discussion
default Loading...



Loading wiki pages...

Wiki Version:
Project for Accelerated Sharing of Treatment Results to Meet Novel Challenges -- KEY POINTS • Potential to Quickly Win the War on COVID-19 • Utilize Evidence From, By and For Physicians and Clinics. • Bridge the gap between "anecdotal" and "gold standard" evidence for promising treatments • Without an Institutional Review Board (IRB), you may treat patients as usual, tabulate results and share them. No ethical, privacy or regulatory issues are involved. (See suggested form Dataset.xlsx in Files section). • With an IRB, you can quickly do safe, simplified controlled trials. See suggested crossover trial design in Datasets wiki. • Retrospective and current data both welcome. • We wish to share your data as widely and quickly as possible. For maximum effect we will also prepare a more formal study for submission to peer-reviewed journals. Contributors will be mentioned by name, if they wish. ****** This project is also the first step in launching a new scientific journal to explore and evaluate neglected sources of evidence – findings from a great field. Your research papers are also wanted. A major focus here is on hydroxychloroquine and zinc deficiency, but this project is open for objective data on any promising treatments. Empowering individual physicians and clinics, and evaluating therapies that boost our immune system, holds great promise to help society react rapidly enough to face new viral challenges. Questions Why do some people die and others barely get sick from this virus? Is this primary line of inquiry being pursued? Thanks to science and innovation, we are an advanced high-tech society. Has our coronavirus response been up to our best level? Not really. Imagine a middle school science teacher asks this question: "Class, suppose a doctor finds a cure that he says is helping save a lot of lives. How will society respond? A. Ask him to document his claim. B. See if other doctors get similar results. C. Ignore him. D. Make him apply for FDA approval first. The right answer, of course, is A and B, to use the scientific method. That is what this project is about. Contact: fieldtrials at berkeley edu